ATAGI update following weekly COVID-19 meeting – 12 January 2022
Following recent data, ATAGI recommends that severely immunocompromised children between the ages of 5 to 11 years receive a 3rd primary dose of the COVID-19 vaccine to optimise their protection against COVID-19 infection.
Current data has not identified any concerning safety signals in this cohort. ATAGI continues to review and closely monitor reports regarding the safety and efficacy of the COVID-19 vaccine in this age group.
This statement provides a concise summary of the January ATAGI meeting, including the latest recommendations and considerations regarding the safety and efficacy of the COVID-19 vaccine in children ages 5 to 11 years.
To read the full statement, follow the link below:
ATAGI update following weekly COVID-19 meeting - 12 January 2022
Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you?
Scientists around the world are looking at whether protective antibodies in the current COVID-19 vaccines are “sufficiently high” to cover the new Omicron strain. Additionally, the WHO and governments are assessing the severity of the new variant.
Vaccine makers, including Pfizer and Moderna have been working on “next-generation” mRNA vaccines that would be able to target particular variants circulating. Current data suggests that the COVID-19 vaccines used in Australia will protect against severe disease.
To read the full article, please click on the link below:
Omicron variant: will the COVID-19 Pfizer, Moderna, AstraZeneca vaccines protect you?
Moderna says new vaccine for Omicron variant may be ready in early 2022
Moderna Inc. Chief Medical Officer Paul Burton has announced that they are working rapidly to test the current vaccine against the Omicron variant and studying two booster candidates.
Current data suggests that protection against the new strain still exists, depending on the length of time passed from an individual's second vaccine dose.
To read the full article, please follow the link below:
Moderna says new vaccine for Omicron variant may be ready in early 2022
The Conversation: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination
The COVID-19 pandemic has perpetuated rapid medical advancements and technological innovations. Over the last 20 months, we’ve experienced an influx of new vaccines which have proven to be safe and effective in preventing disease.
Scientists and researchers around the world are already working on the next generation of COVID vaccines to help tackle issues regarding waning immunity, storage and delivery, and vaccine hesitancy. Focusing their efforts on making vaccination easier, delivering more durable immunity and protecting against future variants
This article looks at the different considerations for research and technology around the world that will in turn lead to the next generation of COVID vaccines.
Follow the link to read the full article: Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccination